CCL5 and prostate cancer: The tyrosine kinase inhibitor gefitinib inhibits epidermal growth factor receptor (EGFR) activation on MSCs by conditioned medium from PC3 prostate cancer cells (bone metastasis of prostate cancer), leading to decreased secretion of CCL5 [191].